GenSight Biologics reports its cash position as of March 31, 2017
Paris, France, April 26, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today reported its cash position as of March 31, 2017.
Cash and cash equivalents
GenSight Biologics’ cash and cash equivalents amounted to €48.8 million as of March 31, 2017, compared to €54.0 million as of December 31, 2016.
Number of outstanding shares
As of March 31, 2017, GenSight Biologics’ number of outstanding shares was 19,540,453 ordinary shares.
GenSight Biologics will report its financial statements and update for the first half of 2017 on July 28, 2017.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
